Humana (NYSE:HUM) had its price objective boosted by equities research analysts at Leerink Swann from $280.00 to $300.00 in a research note issued on Thursday, Marketbeat.com reports. The firm currently has an “outperform” rating on the insurance provider’s stock. Leerink Swann’s price target would indicate a potential upside of 14.34% from the company’s previous close.
Several other research firms have also issued reports on HUM. BMO Capital Markets upped their target price on shares of Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Cowen reiterated a “buy” rating and issued a $285.00 target price on shares of Humana in a research note on Wednesday, December 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $242.00 target price (down previously from $245.00) on shares of Humana in a research note on Thursday, November 9th. Zacks Investment Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 19th. Finally, Credit Suisse Group reduced their target price on shares of Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a research note on Friday, November 10th. Eight equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $268.26.
Shares of Humana (NYSE HUM) traded down $2.53 during mid-day trading on Thursday, reaching $262.37. 2,018,948 shares of the company’s stock were exchanged, compared to its average volume of 1,227,305. The company has a market cap of $37,850.00, a price-to-earnings ratio of 15.79, a PEG ratio of 1.66 and a beta of 0.93. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. Humana has a fifty-two week low of $197.94 and a fifty-two week high of $293.35.
Humana declared that its Board of Directors has authorized a share buyback program on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.
In related news, SVP Jody L. Bilney sold 7,054 shares of the business’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the transaction, the senior vice president now directly owns 11,704 shares of the company’s stock, valued at approximately $2,901,304.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Brian P. Leclaire sold 1,679 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the transaction, the senior vice president now directly owns 9,888 shares in the company, valued at $2,432,151.36. The disclosure for this sale can be found here. Insiders sold a total of 10,115 shares of company stock worth $2,501,627 over the last three months. 0.80% of the stock is owned by insiders.
Large investors have recently modified their holdings of the stock. WFG Advisors LP boosted its holdings in shares of Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after buying an additional 20 shares during the last quarter. Fieldpoint Private Securities LLC purchased a new position in shares of Humana in the 3rd quarter worth about $115,000. ClariVest Asset Management LLC purchased a new position in shares of Humana in the 3rd quarter worth about $144,000. Daiwa SB Investments Ltd. boosted its holdings in shares of Humana by 44.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after buying an additional 220 shares during the last quarter. Finally, Pettee Investors Inc. purchased a new position in shares of Humana in the 3rd quarter worth about $207,000. 94.39% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/08/leerink-swann-boosts-humana-hum-price-target-to-300-00.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.